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Abstract
Background: The number of times that articles are cited by is widely used to evaluate the impact of an article or
an individual author has on its scientific community. This bibliometric analysis aimed to explore the top classic
citations in pancreatic cancer (PC) research.
Methods: A computerized literature search was conducted using the database, the Science Citation Index
Expanded. The top 100 highly cited articles were included and further analyzed.
Results: The most cited article had 3,032 citations, with a mean of 626 citations per paper. These highly cited
articles were published in 37 journals, led by Cancer Research (15 articles). Of the 100 articles, 40 were observational
studies, 36 dealt with basic science, and 14 were randomized controlled trials. These articles came from 11
countries, with the USA contributing 79 articles. Fifty-one institutions produced these 100 citation classics, led by
Johns Hopkins University (20 articles). Twenty-seven persons authored two or more of the top-cited articles, led by
Kern SE (6) and Yeo CJ (5).
Conclusions: This analysis of the top highly cited articles allows for the recognition of major advances in PC
research and gives a historic perspective on the progress of this specialty of PC research.
Keywords: Citation classic, Pancreatic cancer
Background
Currently, pancreatic cancer (PC) remains a fatal disease
with poor prognosis [1]. In recent decades, significant
growth has been seen in the field of pancreatic cancer
research. Though these advancements in PC research
are widely known by the clinicians, the most important
papers are not commonly known and identified.
Recently, many specialities and diseases have identified
and analyzed their “citation classics” (the articles most
highly cited or the articles cited more than 100 times) in
their fields [2–6]. Besides, there were also a few journals
which published their own citation classics [7, 8]. The
purpose of our present study was to identify the top
classic citations in PC research.
Methods
A computerized literature search was conducted using
the database, the Science Citation Index Expanded
founded by the Institute for Scientific Information
(1966–Sep 25, 2015) [9]. The relevant articles were
identified by searching using a highly sensitive search
strategy, and all phases of the search strategy are
shown in Table 1. There was no journal restriction.
The top 100 highly cited articles were included for
further analysis.
The titles and abstracts of the articles would be reviewed
to estimate whether they are related to PC research. We an-
alyzed the articles and calculated the data according to the
following predefined items: number of citations, publication
year, country of origin, institution, journal, publication type
(e.g., basic science, observational study), and authorship
(only calculating the corresponding, first, and second
author).
Results
The literature search involved 27,413 publications using
the Science Citation Index Expanded founded by the
Institute for Scientific Information (ISI) (1966–present).
The top 100 highly cited articles were showed in Table 2
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according to the number of citation. The most frequently
cited article received 3032 citations, and the least fre-
quently cited article received 330 citations. Twelve articles
received more than 1000 citations. The mean number of
citations per paper was 626. We also evaluated the 10-
year citations of the paper published before 2006. The
most frequently cited article received 1354 citations, and
the least frequently cited article received 5 citations. The
proportions of 10-year after publication of 1970–1979,
1980–1989, 1990–1999, and 2000–2005 were 20.5, 41.2,
49.8, and 68.0%, respectively (Table 3).
The top 100 classic citations were published from
1970 to 2013. The decade of 1990–1999 produced the
most classic citations with 42 ones, followed by 37 ones
from 2000 to 2009 (Fig. 1). The most classic papers
published were 7 ones in 1993, 1997, 2004, and 2007.
The top-cited articles were published in 37 high-
impact journals (Table 4), led by Cancer Research (15
articles), followed by Journal of Clinical Oncology (9),
Annals of Surgery (9), and New England Journal of
Medicine (8).
The 100 top-cited articles came from 11 countries,
with the USA producing 79 articles, followed by UK
with 6 ones, and Germany with 4 ones (Table 5).
Altogether, 51 institutions produced these 100 top-
cited papers. Among them, 12 institutions produced
2 or more of the top-cited papers (Table 6), led by
Johns Hopkins University (20 articles), followed by
the University of Texas (7 articles), and Harvard
University (7 articles).
In the 100 top-cited articles, 3 ones were authored by
a single author and 5 ones by 2 authors. Twenty-seven
persons authored two or more of the top citations.
Table 6 presents a list of these “most frequent authors,”
which is led by Kern SE who authored 6 classic papers
and Yeo CJ who authored 5 classic papers.
Of the 100 top-cited papers, 40 were observational
studies, 36 dealt with basic science, and 14 were ran-
domized controlled trials (RCT). The other 9 papers
were 7 review articles, 1 conference consensus, and 1
meta-analysis (Table 7). Among the 56 clinical studies
(40 observational studies, 14 RCTs, and 2 meta-
analyses), 39 were about treatment (including 14 chemo-
therapy, 9 chemoradiotherapy, and 16 surgery), 9 were
about diagnosis (2 radiographic and 8 laboratory), and 7
were about epidemiology (Table 8).
Discussion
Bibliometric analysis of most frequently cited articles and
the journals in which they appear serves several purposes.
It identifies and emphasizes the impact of the work of our
colleagues and predecessors, recognizes key advances in
pancreatic cancer research, and adds useful perspective on
historical developments in this specialty. The use of cit-
ation analysis to examine the pancreatic cancer research
literature also reveals quantitative information about au-
thors, topics, and journals that is helpful in identifying
classic works and high-impact journals. As far as we
know, this is the first bibliometric analysis on the top cita-
tions in the field of pancreatic cancer research.
Although it is very difficult to provide a detailed ana-
lysis of all the 100 top citations, some interesting obser-
vations could be made about the top 10. These 10
classic citations revealed major advances in PC research
and a number of hot topics in the past five decades. The
leading article by Burris HA 3rd reported the first large-
size RCT on gemcitabine in advanced PC which may be
the most important advance in the field of medical treat-
ment of PC research in the past decades. At position 2,
Moore MJ firstly described a large-size clinical RCT of
erlotinib plus gemcitabine compared with gemcitabine
alone in patients with advanced PC. At position 3 and 5,
core signaling pathways revealed by global genomic ana-
lyses and mutant c-K-ras genes were reported. At pos-
ition 4 and 9, identification of pancreatic cancer stem
cells and the effect on tumor growth and metastatic ac-
tivity of distinct populations of pancreatic cancer stem
cells were described. At position 6, Guillemin R founded
that growth hormone-releasing factor from a human
pancreatic tumor could cause acromegaly. At position 7,
Conroy T conducted a RCT of FOLFIRINOX versus
gemcitabine for metastatic pancreatic cancer. At position
8, Warshaw AL reviewed the advances of pancreatic
cancer. At position 10, Neoptolemos JP compared che-
moradiotherapy and chemotherapy after resection of
pancreatic cancer in a RCT.
Most of the classic articles are still regularly cited now.
Time has much effect on an article’s citation, because of
that an article’s citations depend on its publication time,
as citations accumulate over time. Hence, the group of
the highly cited articles could be dominated by the earli-
est papers. However, the decade 1990–1999 and 2000–
2009 produced the most classic citations with 42 and 37
ones, respectively, which indicated that much more ad-
vances were achieved in these two decades than the
others, such as gemcitabine. Besides, in the most recent
years, many new journals were developed, and therefore,
the number of published articles has grown rapidly and
more references are cited.
There were 15, 9, and 9 classic articles published in
Cancer Research, Journal of Clinical Oncology, and
Table 1 All phases of the search strategy to identify potential
articles
title=(pancreatic or pancreas) AND title=(adenocarcinoma or
adenocarcinomas or carcinoma or carcinomas or cancer or cancers or
neoplasm or neoplasms or tumor or tumors or malignancy or
malignancies)
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Table 2 The top 100 cited articles in pancreas cancer research
Rank Article No. of
citations
1 Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
3032
2 Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966.
1731
3 Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
Science. 2008;321(5897):1801-1806.
1706
4 Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030-1037. 1620
5 Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.
Cell. 1988;53(4):549-554.
1567
6 Guillemin R, Brazeau P, Böhlen P, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.
Science. 1982;218(4572):585-587.
1291
7 Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med.
2011;364(19):1817-1825.
1282
8 Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326(7):455-465. 1254
9 Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic
activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313-323.
1252
10 Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection
of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
1133
11 Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse
model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
1084
12 Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363(9414):1049-57. 1013
13 Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in
pancreatic adenocarcinoma. Nat Genet. 1994;8(1):27-32.
989
14 Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent
resection of pancreatic cancer - A Randomized controlled trial. JAMA. 2007;297(3):267-277.
978
15 Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-1617. 951
16 Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328(20):1433-1437. 948
17 Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature.
2003;425(6960):851-856.
917
18 Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
Cancer Cell. 2003;4(6):437-435.
906
19 Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment
of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756-2761.
866
20 Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic
indicators. J Gastrointest Surg. 2000;4(6):567-579.
844
21 Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature.
2010;467(7319):1114-1117.
828
22 Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Arch Surg. 1985;120(8):899-903.
738
23 Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.
Ann Surg. 1995;221(6):721-731.
702
24 Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high
dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil:
The Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705-1710.
699
25 Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med.
2013;369(18):1691-1703.
691
26 Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas
and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776-782.
677
27 Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely
metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483.
647
28 Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal
pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-1908.
639
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29 Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.
J Gastrointest Surg. 2006;10(9):1199-1210.
633
30 Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2(12):897-909. 626
31 Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally
advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-3516.
576
32 Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and
tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996;93(8):3636-3641.
567
33 Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Cancer Res. 1999;59(5):987-990.
566
34 Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer.
2007;120(5):1046-1054.
558
35 Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165(1):68-72. 557
36 Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen
detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43(11):5489-5492.
548
37 Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791):607-620. 542
38 Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer. 1987;60(9):2284-2303. 538
39 Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study
of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide
hybridization. Am J Pathol. 1993;143(2):545-554.
530
40 Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature.
2010;467(7319):1109-1113.
523
41 Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and
intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977-987.
506
42 Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res.
1988;16(16):7773-7782.
504
43 Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary
Pancreatitis Study Group. J Natl Cancer Inst. 1997;89(6):442-446.
503
44 Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human
pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5(1):119-127.
501
45 Huxley R, Ansary-Moghaddam A, Berrington de González A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36
studies. Br J Cancer. 2005;92(11):2076-2083.
497
46 Han HJ, Yanagisawa A, Kato Y, et al. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer.
Cancer Res. 1993;53(21):5087-5089.
494
47 Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev.
2006;20(10):1218-1249.
491
48 Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:
a randomised controlled trial. Lancet. 2001;358(9293):1576-1585.
489
49 Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg.
2004;239(6):788-797.
482
50 Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary
cancer. Ann Oncol. 1996;7(6):593-600.
481
51 Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res.
2008;14(14):4491-4499.
479
52 Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57(9):1731-1734. 478
53 Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in
patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20(15):3270-3275.
473
54 Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really
improving? Ann Surg. 1995;221(1):59-66.
472
54 Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal
adenocarcinoma. Genes Dev. 2003;17(24):3112-3126.
472
56 Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma.
Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223(3):273-279.
471
57 Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Ann Oncol. 1996;7(4):347-353.
461
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58 Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed
from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1-7.
458
59 Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma
in mice and humans. Science. 2011;331(6024):1612-1616.
457
60 Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349-361. 456
61 Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.
Am J Surg. 1991;161(1):120-124.
447
62 Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated
with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24(29):4677-4684.
445
63 Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant
chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-633.
439
64 Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo
in advanced pancreatic cancer. J Clin Oncol. 2004;22(8):1430-1438.
438
65 Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the
surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Ann Surg.
1998;228(4):508-517.
432
66 Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is
associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest.
1992;90(4):1352-1360.
422
67 Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6(8):2969-2972. 417
68 Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new
paradigm for combination therapy in solid cancers. Cancer Res. 2007;67(5):2187-2196.
416
69 Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605-1609. 414
70 Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with
pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586-594.
412
71 Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer
correlates with decreased survival. Gastroenterology. 1993;105(6):1846-1856.
410
72 Warshaw AL, Gu ZY, Wittenberg J, et al. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg.
1990;125(2):230-233.
408
73 Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Cancer Res. 1996;56(23):5360-5364.
405
74 Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4
mutations. N Engl J Med. 1995;333(15):970-974.
400
75 Chang KJ, Nguyen P, Erickson RA, et al. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis
and staging of pancreatic carcinoma. Gastrointest Endosc. 1997;45(5):387-393.
395
76 Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Cancer Res. 1997;57(15):3126-3130.
393
77 Rösch T, Braig C, Gain T, et al. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with
conventional sonography, computed tomography, and angiography. Gastroenterology. 1992;102(1):188-199.
391
78 Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase
inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60(11):2926-2935.
387
79 Lan MS, Batra SK, Qi WN, et al. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem.
1990;265(25):15294-15299.
384
80 MacMahon B, Yen S, Trichopoulos D, et al. Coffee and cancer of the pancreas. N Engl J Med. 1981;304(11):630-633. 383
81 Lieberman MD, Kilburn H, Lindsey M, et al. Relation of perioperative deaths to hospital volume among patients undergoing
pancreatic resection for malignancy. Ann Surg. 1995;222(5):638-645.
382
82 Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res.
2008;68(3):918-926.
378
83 Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced
non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22(22):4456-4462.
376
84 Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based
chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019-1026.
371
85 Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the
disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82(1):111-115.
364
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Annals of Surgery, respectively, which showed that these
three journals were the leading ones in the speciality of
PC research. New England Journal of Medicine, Journal
of the American Medical Association, and Lancet were
the most famous general medical journals, and 16 arti-
cles were published in these three journals. The fact that
papers on PC research are regularly published on these
journals documents that PC is an important topic and
health issue to humans.
The finding that most top-cited articles originated from
the USA is anticipatory and is consistent with the origins
of the citation classics in other fields [2–5]. Furthermore,
11 of the 12 top productive institutions lie in USA. These
findings confirm the USA’s overwhelming impact on PC
research because of its large population and abundant
financial supports to the scientific community.
The list of the most frequent authors on PC research
just gave a sample of some of the best recognized
Table 2 The top 100 cited articles in pancreas cancer research (Continued)
85 Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine
alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946-3952.
364
87 Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with
pancreatic adenocarcinoma. Cancer Res. 1993;53(11):2472-2474.
361
88 Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced
pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
JAMA. 1985;253(14):2061-2067.
353
89 Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies
multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63(10):2649-2457.
349
90 Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br J Cancer. 1991;64(6):1076-1082.
347
91 Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma
of the pancreas. Invest New Drugs. 1994;12(1):29-34.
345
91 Mack TM, Yu MC, Hanisch R, et al. Pancreas cancer and smoking, beverage consumption, and past medical history.
J Natl Cancer Inst. 1986;76(1):49-60.
345
93 Crile G Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma.
Surg Gynecol Obstet. 1970;130(6):1049-1053.
341
93 Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic
cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13(3):565-569.
341
95 Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with
pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15(3):928-937.
340
96 Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer.
Ann Surg. 1998;228(3):429-438.
339
97 Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement
of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54(11):3025-3033.
337
98 Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors
progress through different genetic lesions. Cancer Res. 1994;54(6):1556-1560.
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1970–1979 1 341 70 20.5
1980–1989 12 7629 3145 41.2
1990–1999 42 22,971 11,434 49.8
2000–2005 21 12826 8718 68.0 Fig. 1 The numbers of classic citations in the past decades
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scientists in PC research. It was not surprising that not
all famous scientists in PC research were mentioned,
which was consistent with the previous studies on top
citation classics [2–5]. The editors may consider invit-
ing these researchers to submit subsequent manuscripts
or reviews. In many cross-discipline studies of highly-
cited articles, reviews usually predominate [10]. In this
study, there were 7 reviews in the top 100 cited articles.
Some of the articles reported are not original
research articles, except the reviews. They are highly
cited because they are “opinion” articles, that for sev-
eral reasons became classic in the field of pancreatol-
ogy. For example, the article from Crile keeps being
cited since it is an example of the so-called nihilistic
approach to pancreatic cancer. Although they are not
original research articles, they are also very important
to the advance of pancreatic cancer, and thus, they
are constantly cited.
In this literature analysis, by searching for “pancre-
atic cancer research”, the top articles were mainly on
oncology and basic cancer research. This paper maybe
Table 4 Journals in which the top 100 cited articles were
published
Rank Journals No. of articles
1 Cancer Research 15
2 Journal of Clinical Oncology 9
2 Annals of Surgery 9
4 New England Journal of Medicine 8





10 Proceedings of the National Academy of Sciences 2
10 Journal of the National Cancer Institute 2
10 Journal of Gastrointestinal Surgery 2
10 Genes & Development 2
10 Gastroenterology 2
10 Clinical Cancer Research 2
10 Cell 2
10 Cancer Cell 2
10 British Journal of Surgery 2
10 British Journal of Cancer 2
10 Archives of Surgery 2
10 Annals of Oncology 2
10 American Journal of Surgery 2
23 Surgery, gynecology & obstetrics 1
23 Nucleic Acids Research 1
23 Nature Reviews Cancer 1
23 Nature Genetics 1
23 Journal of Immunology 1
23 Journal of Clinical Investigation 1
23 Journal of Biological Chemistry 1
23 Journal of the American College of Surgeons 1
23 Investigational New Drugs 1
23 International Journal of Cancer 1
23 Gastrointestinal Endoscopy 1
23 Cell Stem Cell 1
23 Anticancer Research 1
23 American Journal of Surgical Pathology 1
23 American Journal of Pathology 1
Table 5 Countries of origin of the top 100 cited articles












Table 6 Institutions of origin with two or more top-cited
articles
Rank Institutions No. of
articles
1 Johns Hopkins University 20
2 University of Texas 7
2 Harvard University 7
4 Memorial Sloan-Kettering Cancer Center 4
4 University of California, Irvine 4
4 University of Pennsylvania 4
7 Mayo Clinic Rochester 3
7 Ohio State University 3
9 Liverpool University 2
9 National Institute of Arthritis, Diabetes, and Digestive
and Kidney Diseases, NIH
2
9 New York Medical College 2
9 University of Michigan 2
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just provides a good view of the medical part of the
research world and does not fully reflect the great
contribution to this field from surgeons. Some im-
portant surgical advances were achieved before several
decades, when not many medical journals were pub-
lished and the number of citations could not fully
reflect the influence.
Conclusions
The top-cited articles identify topics, authors, and institu-
tions that contributed to major advances in the speciality
of PC research. This analysis allows for the recognition of
major advances in PC research and gives a historic
perspective on the progress of PC research.
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